Hongda Zhu1, Daniel Duran2, Lingyang Hua1, Hailiang Tang1, Hong Chen3, Ping Zhong1, Kang Zheng1, Yongfei Wang1, Xiaoming Che1, Weimin Bao1, Yin Wang3, Qing Xie4, Ye Gong5. 1. Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 2. Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA. 3. Department of Neuropathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. 4. Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: neurosurgeon.qing@gmail.com. 5. Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: drgongye@163.com.
Abstract
OBJECTIVE: Hemangiopericytoma (HPC) is a rare mesenchymal tumor that tends to affect the central nervous system and is associated with distant metastasis and a high recurrence rate. The purpose of this study was to analyze the prognostic factors in patients with primary HPC who received surgical treatment. METHODS: This retrospective study reviewed all adult patients with primary HPC of the central nervous system treated from 2001 to 2009 at our institution. Clinical information, adjuvant radiation, and expression levels of Ki-67 and p53 were correlated with patient outcomes. RESULTS: The final analysis included 103 patients. The mean follow-up period was 75.9 months ± 36.5 (range, 1-165 months). There was a significant difference in progression-free survival (PFS) (P < 0.001) and overall survival (P = 0.014) between patients who underwent gross total resection versus subtotal resection. Expression of p53 was found in 48.5% of patients and showed utility as an independent unfavorable prognostic factor for PFS (P = 0.006). Multivariate analysis revealed that only extent of tumor resection (P = 0.004) and p53 expression (P = 0.024) were independent prognostic factors for PFS. Adjuvant radiation was found to extend PFS only in the p53-negative expression group (P = 0.044). CONCLUSIONS: Gross total resection significantly improves the outcome of patients with primary HPCs, whereas adjuvant radiation contributes significantly to PFS only in patients with negative p53 expression and in patients with incomplete resections. Extent of resection and p53 expression may serve as prognostic markers for the outcome of patients with primary HPC.
OBJECTIVE: Hemangiopericytoma (HPC) is a rare mesenchymal tumor that tends to affect the central nervous system and is associated with distant metastasis and a high recurrence rate. The purpose of this study was to analyze the prognostic factors in patients with primary HPC who received surgical treatment. METHODS: This retrospective study reviewed all adult patients with primary HPC of the central nervous system treated from 2001 to 2009 at our institution. Clinical information, adjuvant radiation, and expression levels of Ki-67 and p53 were correlated with patient outcomes. RESULTS: The final analysis included 103 patients. The mean follow-up period was 75.9 months ± 36.5 (range, 1-165 months). There was a significant difference in progression-free survival (PFS) (P < 0.001) and overall survival (P = 0.014) between patients who underwent gross total resection versus subtotal resection. Expression of p53 was found in 48.5% of patients and showed utility as an independent unfavorable prognostic factor for PFS (P = 0.006). Multivariate analysis revealed that only extent of tumor resection (P = 0.004) and p53 expression (P = 0.024) were independent prognostic factors for PFS. Adjuvant radiation was found to extend PFS only in the p53-negative expression group (P = 0.044). CONCLUSIONS: Gross total resection significantly improves the outcome of patients with primary HPCs, whereas adjuvant radiation contributes significantly to PFS only in patients with negative p53 expression and in patients with incomplete resections. Extent of resection and p53 expression may serve as prognostic markers for the outcome of patients with primary HPC.
Authors: Connor J Kinslow; Samuel S Bruce; Ali I Rae; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Adam M Sonabend; Tony J C Wang Journal: J Neurooncol Date: 2018-02-09 Impact factor: 4.130
Authors: Seung Hyuck Jeon; Sung-Hye Park; Jin Wook Kim; Chul-Kee Park; Sun Ha Paek; Il Han Kim Journal: J Neurooncol Date: 2018-01-11 Impact factor: 4.130
Authors: Joo Ho Lee; Seung Hyuck Jeon; Chul-Kee Park; Sung-Hye Park; Hong In Yoon; Jong Hee Chang; Chang-Ok Suh; Su Jeong Kang; Do Hoon Lim; In Ah Kim; Jin Hee Kim; Jung Ho Im; Sung-Hwan Kim; Chan Woo Wee; Il Han Kim Journal: Cancer Res Treat Date: 2021-03-24 Impact factor: 4.679